A systematic review [50] of studies on clinical implications of predictive APOE genotyping for late-onset AD, published between 2008 and 2018, identified 5 studies addressing the safety of APOE disclosure and 80% (5/6) were from the REVEAL studies. This evidence concerns the gene APOE and Alzheimer disease.